76 related articles for article (PubMed ID: 15054688)
1. [Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
Böger RH
Dtsch Med Wochenschr; 2004 Apr; 129(15):820-4. PubMed ID: 15054688
[No Abstract] [Full Text] [Related]
2. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension.
Triches CB; Mayer S; Quinto BMR; Batista MC; Zanella MT
J Clin Hypertens (Greenwich); 2018 May; 20(5):935-941. PubMed ID: 29604155
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
Szuba A; Podgórski M
Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Böger RH
Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
[TBL] [Abstract][Full Text] [Related]
5. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
[TBL] [Abstract][Full Text] [Related]
6. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
Zhang WR; Tao LJ; Chen BM
Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.
Morimoto H; Nakao K; Fukuoka K; Sarai A; Yano A; Kihara T; Fukuda S; Wada J; Makino H
Nephrol Dial Transplant; 2005 Dec; 20(12):2775-82. PubMed ID: 16221689
[TBL] [Abstract][Full Text] [Related]
11. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Kielstein JT; Zoccali C
Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
[TBL] [Abstract][Full Text] [Related]
13. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.
Oğuz A; Uzunlulu M; Yorulmaz E; Yalçin Y; Hekim N; Fici F
Anadolu Kardiyol Derg; 2007 Dec; 7(4):383-7. PubMed ID: 18065333
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Vallance P; Leiper J
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
[TBL] [Abstract][Full Text] [Related]
17. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects.
Schulze F; Maas R; Freese R; Schwedhelm E; Silberhorn E; Böger RH
Eur J Clin Invest; 2005 Oct; 35(10):622-6. PubMed ID: 16178881
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
Krzyzanowska K; Mittermayer F; Krugluger W; Schnack C; Hofer M; Wolzt M; Schernthaner G
Atherosclerosis; 2006 Nov; 189(1):236-40. PubMed ID: 16414052
[TBL] [Abstract][Full Text] [Related]
19. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
20. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence.
Scalera F; Borlak J; Beckmann B; Martens-Lobenhoffer J; Thum T; Täger M; Bode-Böger SM
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1816-22. PubMed ID: 15308550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
